Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Published:2017-09-14 Issue:11 Volume:130 Page:1375-1377
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Connors Joseph M.¹^ORCID,Ansell Stephen M.²^ORCID,Fanale Michelle³,Park Steven I.⁴,Younes Anas⁵

Affiliation:

1. British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada;

2. Mayo Clinic, Rochester, MN;

3. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX;

4. Hematology-Medical Oncology, Levine Cancer Institute, Charlotte, NC; and

5. Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/11/1375/1402383/blood784678.pdf

Reference11 articles.

1. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi;Merli;J Clin Oncol,2016

2. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial;Carde;J Clin Oncol,2016

3. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma;Radford;N Engl J Med,2015

4. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma;Connors;Blood,2015

5. US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816;Press;J Clin Oncol,2016

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons;Surgical Oncology Clinics of North America;2024-04

2. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy;European Journal of Neurology;2024-03-21

3. Invited commentary on “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study”;Cancer Treatment and Research Communications;2024

4. Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma;Journal of Chemotherapy;2023-11-16

5. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma;International Journal of Molecular Sciences;2023-08-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3